Defendant

Jazz Pharmaceuticals PLC

14 cases as defendant.

Cases
14
Active
1
13 closed
Filed
2020–2021
Top venue
N D Ill
7 cases

Company profile

Company overview. Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is an Irish-domiciled, publicly traded biopharmaceutical company headquartered at Waterloo Exchange, Waterloo Road, Dublin 4, Ireland. It was founded in 2003 by Bruce Cozadd (who remains chairman and CEO) and has been listed on Nasdaq since its 2007 IPO. Reported headcount is roughly 2,890 employees (year-end 2025), with trailing revenue around $4.1–4.3 billion. It is not a subsidiary; it is the publicly listed parent. Operational hubs include Palo Alto and Philadelphia, with manufacturing in Ireland, Italy, and the U.S.

Products / operations. Jazz develops and commercializes medicines in neuroscience and oncology. Neuroscience: Xywav and Xyrem (sodium oxybate) for narcolepsy and idiopathic hypersomnia, and Epidiolex (cannabidiol) for severe epilepsies. Oncology: Rylaze/Enrylaze, Zepzelca, Ziihera (zanidatamab), Defitelio, Vyxeos, and Modeyso, plus pipeline candidates such as dordaviprone and JZP815. Portfolio expansion has come largely through acquisition — notably GW Pharmaceuticals (2021, ~$7.2 billion) and Chimerix (2025, ~$935 million).

Patent-litigation posture. Jazz is an operating company, not an NPE. In the structured data it appears in 23 tracked matters and as plaintiff in zero. Its defendant-side record here reflects antitrust and reimbursement litigation over its oxybate franchise rather than patent-assertion suits against it. The venue cluster is N.D. Cal. and the Northern District of Illinois, alongside D. Minn. and D. Mass.; no Eastern District of Texas presence.

Notable cases and context. Most tracked matters are consolidated in In re Xyrem (Sodium Oxybate) Antitrust Litigation, MDL No. 20-md-02966-RS (N.D. Cal.), brought by payors including UnitedHealthcare, the Blue Cross and Blue Shield Association, the Government Employees Health Association, the City of Providence, and the Self-Insured Schools of California. Plaintiffs alleged pay-for-delay agreements with generic manufacturers and "product hopping" from Xyrem to Xywav. The court granted final approval in October 2025 to $195 million in settlements ($145 million from Jazz, $50 million from Hikma). A separate qui tam matter, United States ex rel. Leonardo Sorgi v. Jazz Pharmaceuticals (D. Mass., 2021), also names the company. Jazz has stated it entered settlements in the Xyrem antitrust litigation; the merits of individual claims are not assessed here.

Filing activity

2020: 13 cases13'202021: 1 case'21
Cases filed per year naming Jazz Pharmaceuticals PLC as defendant.

United States ex rel. Leonardo Sorgi v. Jazz Pharmaceuticals PLC et al.

active
Docket:
1:21-cv-10891-PBS
Filed:
2021-05-27
Patents:8772306

Collateral False Claims Act case concerning the '306 patent. Relator alleges Jazz defrauded the PTO in obtaining the '306 patent; the United States and several states declined to intervene, an amended complaint was filed Sept 1, 2024, and Jazz's motion to dismiss was filed Dec 2, 2024, with oral argument Apr 2, 2025.

Hollman v. Jazz Pharmaceuticals PLC

consolidated into/related to MDL
Docket:
3:20-cv-06491
Court:
N.D. Cal.
Filed:
2020-09-16
Patents:8263650

Indirect purchaser class action by Hollman against Jazz; consolidated into/related to the Xyrem MDL.

Government Employees Health Association, Inc. v. Jazz Pharmaceuticals PLC

dismissed
Docket:
1:20-cv-03673
Court:
N.D. Ill.
Filed:
2020-06-23
Terminated:
2020-07-14
Patents:6780889

Antitrust/payor action in N.D. Ill. against Jazz Pharmaceuticals; US 6,780,889 is named among the patents at issue. Terminated on 2020-07-14, consistent with the July 2020 voluntary dismissals of payor suits to pursue claims in the N.D. Cal. MDL.

Untitled case

terminated
Court:
N.D. Ill.
Filed:
2020-06-23
Terminated:
2020-07-14
Patents:7262219

Antitrust action brought by a Blue Cross/Blue Shield-related plaintiff; the '219 patent appears in the record.

Blue Cross affiliate/related v. Jazz Pharmaceuticals PLC

terminated
Docket:
1:20-cv-03673
Court:
N.D. Ill.
Filed:
2020-06-23
Terminated:
2020-07-14
Patents:8263650

Blue Cross affiliate/related antitrust action terminated July 14, 2020.

City of Providence, Rhode Island v. Jazz Pharmaceuticals PLC

Docket:
3:20-cv-04064-LB
Court:
N.D. Cal.
Filed:
2020-06-18
Patents:6780889

Antitrust action in N.D. Cal. against Jazz Pharmaceuticals; the complaint names US 6,780,889 among the patents at issue. The narrative describes it as a payor/indirect-purchaser Xyrem antitrust action.

Unnamed plaintiff v. Jazz Pharmaceuticals PLC

terminated
Docket:
1:20-cv-03543
Court:
N.D. Ill.
Filed:
2020-06-17
Terminated:
2020-07-15
Patents:6780889

Antitrust/payor action in N.D. Ill. against Jazz Pharmaceuticals; US 6,780,889 is named among the patents at issue. Terminated on 2020-07-15.